Latest Healthcare News

Stakk has executed a five-year US$9 million agreement with US banking technology provider Candescent, with its AI-powered cheque and document intelligence already deployed. The contract commits approximately US$1.8 million in annual revenue through 2030 and is expected to contribute above Stakk’s FY2027 revenue milestone.

Promisia Healthcare has completed its acquisition of Chatswood Retirement Village after receiving shareholder approval in August. The vendors were paid through the issue of 1 million ordinary shares and 1 million unquoted convertible notes, leaving key transaction terms to be assessed in future disclosures.

Vection Technologies delivered its first positive full-year operating cash flow and a sharp rise in adjusted EBITDA in FY26. Yet the audited report warns that continued operations depend on stronger sales, margin gains, cost reductions and potential access to further capital.

Iperion reported a lower loss for the year ended 31 March 2026, but its cash reserves and net assets fell sharply, leaving the NZX-listed materials company reliant on related-party funding and director support. Its Pathoglaze manufacturing operation is also being moved from Malaysia to Singapore while customer trials continue.

Alcidion will roll out its Miya Flow software across four Northern Care Alliance hospitals under a new A$7.5 million contract. About A$4.5 million is expected to be recognised as revenue in the current year, including a six-month renewal of the existing ExtraMed system during implementation.

RAM Essential Services Property Fund has posted a $30.1 million FY2026 statutory loss as property values weakened, while its planned $218.6 million retail sale prepares the fund for a healthcare-focused reset. The transaction could reduce gearing to 16.8%, but FY2027 distribution guidance is below the latest payout and refinancing remains unfinished.

TrivarX has made Stabl-Im its central development bet, but the ASX-listed health technology company also reported an $8.76 million FY2026 loss and an auditor-flagged material uncertainty over its ability to continue without further funding. The planned Phase 1 study remains subject to regulatory, ethics and operational clearances.

Memphasys will receive an A$3.5 million advance from major shareholder Peters Investments to expand Felix production, inventory and sales capacity as repeat orders emerge across international markets. The funding carries a 12.5% interest rate, potential equity dilution and requires shareholder and ASX approvals before the convertible notes can be issued.

Stakk has secured a live signature verification engagement for use by the United States Federal Bureau of Investigation through ParaScript, with the agreement running to December 2027. The company says the contract will contribute meaningfully to its FY2027 revenue target, now expected to exceed $55 million, although its value remains confidential.

Cochlear is defending a class action filed in the Supreme Court of Victoria over its FY26 underlying net profit forecast. The claim covers investors who acquired interests in Cochlear shares between 15 August 2025 and 21 April 2026.

Firebrick Pharma has approved a phased push into US retail pharmacies after Nasodine online sales grew by more than 200% in FY26. Up to six regional pharmacy groups representing about 700 stores have expressed strong interest in early orders, although no binding orders have been disclosed.

Embelton Limited (ASX:EMB) grew revenue, profit and operating cash flow in FY2026 despite subdued residential construction, while maintaining its 35-cent fully franked annual dividend. The flooring and engineering group is leaning further into infrastructure, data centres, healthcare and other commercial work, although its near-term contracting pipeline remains modest.